Brooks and Kubler Hunt RH, Harper S, Watson DJ, et al. 2003b. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol, 98:1725–33. Jansen JP, Hunsche E, Choy E, et al. 2005. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK [abstact]. Annual Meeting of the European League Against Rheumatism, 8–11 June 2005, Vienna, Austria. FRI0475. Jarrett SJ, Mcgonagle D, Marzo-Ortega H, et al. 2004. Etoricoxib reduces the need for biologic therapy in ankylosing spondylitis (AS) but has no effect on magnetic resonance imaging. Results from an open study [abstract]. American College of Rheumatology 68th Annual Scientific Meeting, 16–21 October 2004, San Antonio, TX, USA. 1634. Kassahun K, McIntosh IS, Shou M, et al. 2001. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos, 29: 813–20. Leung AT, Malmstrom K, Gallacher AE, et al. 2002. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin, 18:49–58. Malmstrom K, Ang J, Fricke JR, et al. 2005. The analgesic effect of etoricoxib relative to that of two opioid-acetaminophen analgesics: a randomized, controlled single-dose study in acute dental impaction pain. Curr Med Res Opin, 21:141–9. Malmstrom K, Kotey P, Cichanowitz N, et al. 2003. Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. Gynecol Obstet Invest, 56:65–9. Malmstrom K, Kotey P, Coughlin H, et al. 2004a. A randomized, double- blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin J Pain, 20:147–55. Malmstrom K, Sapre A, Couglin H, et al. 2004b. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther, 26:667–79. Martin M, Hunsche E, Boice J, et al. 2005. An economic cost analysis of etoricoxib versus indomethacin in the treatment of acute gouty arthritis in the UK [abstract]. Annual Meeting of the European League Against Rheumatism, 8-11 June 2005, Vienna, Austria. FRI0472. Matsumoto AK, Collantes E, Melian A, et al. 2003a. Treatment with etoricoxib resulted in clinical improvement of rheumatoid arthritis (RA) in two randomized active comparator-controlled 52-week trials [abstract]. Annual Meeting of the European League Against Rheumatism, 18–21 June, 2003, Lisbon, Portugal. THU0249. Matsumoto AK, Melian A, Mandel DR, et al. 2002. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol, 29:1623–30. Matsumoto AK, Zhao PL, Cichanowitz N, et al. 2003b. Etoricoxib is efficacious in patients with rheumatoid arthritis (RA) on concomitant therapy with disease modifying antirheumatic drugs (DMARDs), and/ or low-dose corticosteroids [poster]. American College of Rheumatology 67th Annual Scientific Meeting, 23–28 October 2003, Orlando, FL, USA. 209. Merck 2005. Briefing Package for NDA 21-389: Etoricoxib [online]. Accessed 23 June 2005. URL: http://www.fda.gov/ohrms/dockets/ac/ 05/briefing/2005-4090B1_31_AA-FDA-Tab-T.pdf. Moore A, Phillips C, Hunsche E, et al. 2004. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics, 22:643–60. Ouellet M, Riendeau D, Percival MD. 2001. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A, 98:14583–8. Pallay RM, Seger W, Adler JL, et al. 2004. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol, 33:257–66. Psaty BM, Furberg CD. 2005. COX-2 inhibitors — lessons in drug safety. N Engl J Med, 352:1133–5. Ramey DR, Watson DJ, Yu C, et al. 2005. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib versus. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin, 21:715–22. Ramos-Remus CR, Hunsche E, Mavros P, et al. 2004. Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico. Curr Med Res Opin, 20:691–8. Rasmussen GL, Bourne MH, Rhondeau SM, et al. 2004. Etoricoxib provides pain relief and reduces opioid use in post-orthopedic surgery patients [poster]. Annual European Congress of Rheumatology, 9–12 June 2004, Berlin, Germany. SAT0130. Reginster JY, Fischer CL, Beualieu A, et al. 2004. Etoricoxib demonstrates similiar efficacy and improved gastrointestinal safety compared with naproxen in two 138-week randomized studies of osteoarthritis patients [abstract]. Annual European Congress of Rheumatology, 9–12 June 2004, Berlin, Germany. FRI0394. Riendeau D, Percival MD, Brideau C, et al. 2001. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther, 296:558–66. Rodrigues AD, Halpin RA, Geer LA, et al. 2003. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos, 31: 224–32. Rubin BR, Burton R, Navarra S, et al. 2004. Efficacy and safety profile of treatment with etoricoxib 120mg once daily compared with indomethacin 50mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum, 50:598–606. Schumacher HR, Jr., Boice JA, Daikh DI, et al. 2002. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ, 324:1488–92. Schwartz JI, Greenberg HE, Musser BJ, et al. 2006. Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of paracetamol (acetaminophen) [poster]. Presented at the Annual European congress of Rheumutalogy, 8–11 June 2005, Vienna, Austria. Solomon DH, Karlson EW, Rimm EB, et al. 2003. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation, 107:1303–7. Solomon SD, McMurray JJ, Pfeffer MA, et al. 2005. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med, 352:1071–80. Tacconelli S, Capone ML, Sciullimg, et al. 2002. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX- isozyme activity. Curr Med Res Opin, 18:503–11. van der Heijde D, Baraf HS, Ramos-Remus C, et al. 2005. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty- two-week, randomized, controlled study. Arthritis Rheum, 52: 1205–15. Wagner JA, Kraft W, Burke J, et al. 2001. The COX-2 inhibitor etoricoxib did not alter the anti-platelet of low dose aspirin in health in healthy volunteers [abstract]. Arthritis Rheum, 44(Suppl 9):S135, 498. Warner TD, Mitchell JA. 2004. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J, 18:790–804. 56 Therapeutics and Clinical Risk Management 2006:2(1)